Transitioning from intravenous (IV) to subcutaneous (SC) bortezomib improves efficiencies within the clinic and could also provide a more satisfactory experience for patients with multiple myeloma, reported investigators from Emory University School of Medicine, Atlanta, GA, in a new, late-breaking study published by the American Society of Clinical Oncology for its 2012 annual meeting (J Clin Oncol. 2012 [30 suppl]:e18553).
Chicago, IL—The first oral proteasome inhibitor to enter clinical investigation in myeloma is MLN9708. The current data from a phase 1 study presented at the 2012 American Society of Clinical Oncology meeting suggested that MLN9708 encourages disease control and durability of responses in a heavily pretreated population with multiple myeloma.
Carfilzomib Combinations Should Be Compared with Subcutaneous Bortezomib for Proper Perspective on Neuropathy
Chicago, IL—“Upfront combinations with carfilzomib are certainly showing attractive response rates,” said Robert Z. Orlowski, MD, Associate Professor, Departments of Lymphoma/Myeloma and Experimental Therapeutics, Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, who discussed the results of 3 related studies presented at the ASCO 2012 multiple myeloma oral abstracts session.
Results 1 - 5 of 5